Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

The American Heart Association held its annual Scientific Sessions Nov. 16-18 in Chicago, where healthcare organizations and industry leaders presented the latest research on cardiovascular health.

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

The Windsor Public Schools athletic director announced a new initiative, “EKGs for Elijah,” that offered free heart ...

The American Heart Association and the Arizona Cardinals gathered representatives from 12 local schools for cardiopulmonary ...

A new type of therapy that "edits" a gene in patients with a rare heart condition has been shown to be safe and effective, ...

(HealthDay News) — For patients with obesity and prediabetes, 3 years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

Footage of a man being shoved into a wall by a police officer before being dragged through a front yard has been shared on social media, with SA Police confirming a formal complaint has been made ...

Get dialed in every Tuesday & Friday with quick updates on the world of crypto ...